Filing Flows › Globus Medical (GMED) › Guidance & outlook
Globus Medical (GMED) guidance and outlook
Globus Medical (GMED) lowered its guidance on Nov 5, 2026: Revenue $3.1B for FY2026; Revenue +5.1% for FY2026; EPS $4.95–$5.05 for FY2026; EPS +24.4% to +26.9% for FY2026. Globus Medical's 10-Q filed Nov 5, 2026 makes 5 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $3.1B | lowered |
| Revenue | FY2026 | +5.1% | new |
| EPS | FY2026 | $4.95–$5.05 | reaffirmed |
| EPS | FY2026 | +24.4% to +26.9% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- As our Enabling Technologies become more fully integrated with our Musculoskeletal Solutions, a continued rise in adoption is expected.
- We believe there is significant opportunity to strengthen our position in the U.S. market by increasing the size of our U.S. sales force, and we intend to add additional direct and distributor sales representatives in the future.
- Our principal source of liquidity is cash flow from operating activities, as well as our cash and cash equivalents and marketable securities, which we believe will provide sufficient funding for us to meet our liquidity requirements for the foreseeable future.
- We expect to continue to make investments in surgical sets as we launch new products, increase the size of our U.S. sales force, and expand into international markets.
- There is no assurance that we will be able to secure such additional funding on terms acceptable to us, or at all.
Globus Medical's latest quarter
Globus Medical, Q3 2026: revenue $764M (-0.7% year over year), operating margin 23.2%, net earnings $141M, operating cash flow $265M. The chart follows the revenue to costs, profit and cash.
Questions
Did Globus Medical raise or lower its guidance?
Globus Medical (GMED) lowered its guidance on Nov 5, 2026: Revenue $3.1B for FY2026; Revenue +5.1% for FY2026; EPS $4.95–$5.05 for FY2026; EPS +24.4% to +26.9% for FY2026.
What does Globus Medical expect?
As our Enabling Technologies become more fully integrated with our Musculoskeletal Solutions, a continued rise in adoption is expected. We believe there is significant opportunity to strengthen our position in the U.S. market by increasing the size of our U.S. sales force, and we intend to add additional direct and distributor sales representatives in the future. Our principal source of liquidity is cash flow from operating activities, as well as our cash and cash equivalents and marketable securities, which we believe will provide sufficient funding for us to meet our liquidity requirements f
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.